



EBA'S ADVICE ON SYNTHETIC SECURITISATION

Lars Overby

Head of Credit, Market and Operational Risk Unit – Regulation - EBA

Content of the EBA Report on Synthetic Securitisation

- Published in December 2015, available at: <https://www.eba.europa.eu/-/eba-issues-advice-on-synthetic-securitisation-for-smes>

Market overview

- Issuance and performance of synthetics

Fundamentals of synthetic securitisation

- Definition of credit event; timing and determination of credit protection payments; moral hazard in credit protection contracts; use of synthetic excess spread; termination events; counterparty credit risk


Differentiated regulatory treatment of synthetic securitisation

– based on Commission’s securitisation proposal from Sept. 2015:


- **Scope of regulatory differentiation**
- **Proposed technical amendments to COM’s proposal**
- **Criteria for ‘qualifying’ preferential treatment of some specific synthetic securitisations**

Market overview of Eur. synthetic securitisation

Issuance: balance sheet vs. arbitrage transactions



Issuance: funded vs. unfunded credit protection




Main trends observed:

- Issuance peaked 2004/05: volume 180 bn EUR, majority of transactions of arbitrage type (CDOs)
- Since 2006, gradual decrease in issuance: decrease of arbitrage transactions more pronounced than decrease of balance sheet transactions
- Balance sheet transactions dominated by RMBS and balance sheet CDOs (within CDOs: CLOS and SME exposures were dominant); minor volumes of CMBS and ABS products
- Unfunded credit protection prevailing until 2008 – since 2008 funded protection dominant
- Issuance from 2008 mostly bilateral and not involving activity of rating agencies

Performance of synthetic securitisation

Lifetime default rate (%): balance sheet synthetic tranches, arbitrage synthetic tranches, traditional tranches, per rating grade

(source: S&P, as of 2014 and the EBA calculations)



Main observations from EBA analysis:

- **Arbitrage synthetics** performed **materially worse** than both (i) balance sheet transactions and (ii) traditional securitisation transactions
- The default performance of balance sheet synthetics is **comparable to that of traditional securitisation, for high rating grades**
- The default performance of balance sheet synthetics is **better than that of traditional securitisation, for lower rating grades**

EBA approach to qualifying treatment of synthetic securitisation: 3 pillars

Substantial widening of the scope of framework for preferential treatment of synthetic securitisation premature at this stage

.. but general support to COM's proposal (Art. 270 of sec. regulation of Sept. 2015)

i.e. to restricted extension of preferential 'qualifying' regulatory treatment (applicable to traditional 'qualifying' securitisation) to **some specific segments of synthetic securitisation**, limited to:

Balance-sheet securitisation

SME exposures (at least 80%)

Senior tranches only

Retained by originators

Guaranteed by 0% risk weight public entities



More info on slide 6

Technical amendments to Commission's proposal:

Amended criteria for preferential treatment to reflect specificities of the synthetic securitisation

Extension of the preferential treatment to transactions in which private investors provide credit protection in the form of cash



More info on slide 7

General support to Commission’s proposal

COM’s proposal: preferential regulatory treatment (STS risk weight) is extended to some specific synthetic transactions only, complying with the following conditions:

Reasoning of the EBA’s support for the overarching approach by the COM – as backed by the EBA analysis:

<p>Balance sheet synthetic transactions</p>	<ul style="list-style-type: none"> • Consistently better performance of balance sheet synthetics than arbitrage synthetics
<p>SME portfolio (at least 80%)</p>	<ul style="list-style-type: none"> • Wider evidence of zero defaults of highly rated synthetic tranches of SME exposures; data available for other asset classes less conclusive • Synthetic securitisation has typically been particularly active in corporate/SME class
<p>Senior tranches only</p>	<ul style="list-style-type: none"> • Not sufficient information and evidence on non-senior tranches in synthetic transactions
<p>Retained by originator banks</p>	<ul style="list-style-type: none"> • Prudential treatment of positions retained by originators is a key element shaping the supply side of balance sheet synthetics market • Prudential treatment of investor positions is less relevant factor, given the nature and composition of the investor base (mostly non-bank, sophisticated investors – hedge funds, asset managers, pension funds)
<p>Credit risk transferred through a guarantee to 0% public weighted entities (CB, central government, multilateral development bank, int. organisation)</p>	<p> EBA suggests technical amendment to this criterion – and to extend the framework to fully cash-funded credit protection provided by private investors</p>
<p>The proposal does not extend to establish a fully-fledged STS framework for synthetics securitisation applicable to investors and across asset types</p>	<ul style="list-style-type: none"> • Substantial widening of STS synthetic securitisation framework too premature at this stage

Technical amendments to Commission’s proposal

Extension of framework (i.e. qualifying regulatory treatment) to fully cash-funded credit protection provided by private investors in the form of cash deposited with the originator

- Fully cash funded credit protection represents more than 90% of the issuance volumes surveyed by the EBA in relation to the period 2008-2014 – currently not eligible under COM’s proposal
- Credit protection is immediately accessible, with no risk being incurred by the beneficiary
-
- CRR acknowledges this by imposing a 0% risk weight on cash received to fund credit protection

Amendments to the criteria determining eligibility for qualifying regulatory capital treatment

- Amendments/eliminations of some criteria to fully reflect specificities of synthetic securitisation technique
- Amendments/eliminations of some criteria to focus on originator
 - Disregard for criteria that exclusively reflect an objective of investor protection: e.g. criteria imposing enhanced transparency standards with regards to investors
- Addition of some new criteria:
 - Additional criterion 1 – ensuring that qualifying treatment only targets balance sheet transactions
 - Additional criterion 2 – criteria for eligible credit protection contracts and counterparties
 - Additional criterion 3 to 7 - ensuring that the credit protection contract is structured to adequately protect the position of the originator from a prudential perspective



EUROPEAN BANKING AUTHORITY

Floor 46, One Canada Square, London E14 5AA

Tel: +44 207 382 1776

Fax: +44 207 382 1771

E-mail: info@eba.europa.eu

<http://www.eba.europa.eu>